OUTLOOK THERAPEUTICS INC

$1.76
(as of May 30, 9:30 AM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for OUTLOOK THERAPEUTICS INC

Stock Price
$1.76
Ticker Symbol
OTLK
Exchange
NASDAQ

Industry Information for OUTLOOK THERAPEUTICS INC

Sector
Healthcare
Industry
Biotechnology

Company Description for OUTLOOK THERAPEUTICS INC

Website
https://www.outlooktherapeutics.com
Country
USA
Full Time Employees
23

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is headquartered in Iselin, New Jersey.

Fundamentals for OUTLOOK THERAPEUTICS INC

Market Capitalization
$69,851,528
EBITDA
$-76,323,144
Dividends per Share
P/E Ratio
0.4
Forward P/E Ratio
2.85
Earnings per Share
$4.09
Earnings per Share Estimate Next Year
Profit Margin
Shares Outstanding
42,853,700
Percent Owned by Insiders
28.16%
Percent Owned by Institutions
16.81%
52-Week High
52-Week Low

Technical Indicators for OUTLOOK THERAPEUTICS INC

50-Day Moving Average
200-Day Moving Average
RSI
62.15
ATR
0.15

Analyst Ratings for OUTLOOK THERAPEUTICS INC

Strong Buy
4
Buy
1
Hold
1
Sell
0
Strong Sell
0

News About OUTLOOK THERAPEUTICS INC

May 23, 2025, 6:30 AM EST
ISELIN, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. See more.
May 22, 2025, 4:01 PM EST
ISELIN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. See more.
May 15, 2025, 4:01 PM EST
LYTENAVA™ (bevacizumab gamma) on track for planned first commercial launches in Germany and the United Kingdom (UK) in Q2 CY2025Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 in the United States See more.
Apr 8, 2025, 8:45 AM EST
Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 See more.